Sun Pharma Strikes Settlement with Incyte Over Alopecia Drug Leqselvi
Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has obtained a non-exclusive license for certain patents and will pay Incyte an upfront and royalty payments. Leqselvi has been launched in the US for severe alopecia areata treatment.
- Country:
- India
Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation concerning the Leqselvi drug, addressing severe hair loss (alopecia areata), the company announced on Monday.
The agreement involves dismissing ongoing litigation in the US District Court for New Jersey and includes mutual release from related claims, as stated by the Mumbai-based drug firm.
Sun Pharma will pay Incyte upfront and ongoing royalties in exchange for a limited, non-exclusive patent license, while specific settlement details remain confidential, the company noted.
(With inputs from agencies.)
Advertisement
ALSO READ
NSEL Investors Forum Pushes for Rs 1,950 Crore Settlement: A Major Step Towards Resolution
Gauteng Govt Pays R3.3bn in Second Instalment Toward E-Tolls Debt Settlement
Paresh Rawal Returns: 'Hera Pheri 3' Back on Track After Settlement
EU Invests €5M in Refugee Livelihoods and Food Security in Uganda Settlements
Paramount to pay USD 16 million in settlement with Trump over '60 Minutes' interview
Google News